


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:


1. (Currently Amended) A compound of formula I




its salts, and pharmaceutically acceptable derivatives thereof where


Het is an optionally substituted 5- or 6-membered monocyclic heterocyclic radical or an optionally substituted 9- or 10-membered bicyclic heterocyclic radical, where each heterocyclic radical includes one or more heteroatoms selected from N, S and O;

A is O, S, NH, N(C₁₋₆ alkyl), CH₂O, a direct bond or a bivalent heterocyclic radical of the formula






(b-2),



(b-3), or



(b-4)

where one or more of the carbon atoms within the radicals (b-1) to (b-4) may be optionally substituted with C₁₋₆ alkyl or two carbon atoms in the radicals (b-1) to (b-4) may be bridged with a ~~C₂₋₄ alkylene~~ divalent C₂₋₄alkyl radical, m and n are each independently integers of 1 to 4 inclusive with the proviso that the sum of m and n in radicals (b-1) to (b-4) is 3, 4 or 5;

Z is N or CR⁶ where R⁶ is hydrogen, hydroxy, C₁₋₆ alkyl, C₁₋₆ alkoxy or amino;

Z' is O, S, CHR⁷ or NR⁸ where R⁷ is hydrogen, hydroxy, C₁₋₆ alkyl, C₁₋₆ alkoxy or amino and R⁸ is hydrogen or C₁₋₆ alkyl;

R^4 is hydrogen or C_{1-6} alkyl; and

R^5 is hydrogen, hydroxy, C_{1-6} alkyl or C_{1-6} alkoxy;

Alk is ~~C_{1-7} alkylene~~ divalent C_{1-7} alkyl or a direct bond;

W is O, S, OCH_2 , a direct bond or NR^9 where R^9 is hydrogen or C_{1-6} alkyl;

Ar is an optionally substituted 5- or 6-membered monocyclic aryl radical or an optionally substituted 9- or 10-membered bicyclic aryl radical;


X^1 is C_{1-6} alkyl, C_{3-6} alkenyl, C_{3-6} haloalkenyl, C_{3-6} alkynyl, C_{3-6} haloalkynyl or C_{1-6} alkyl substituted by halo, cyano, nitro, hydroxy, aryl, C_{1-4} alkoxy, C_{2-6} alkoxyalkoxy, acyl or C_{1-4} alkylthio; and

X^2 is hydrogen, cyano, F, Cl, C_{1-4} alkyl, C_{1-4} haloalkyl or a bivalent radical of formula $-(CH_2)_2-$, $-(CH_2)_3-$, $-CH_2O-$ or $-(CH_2)_2O-$ which forms a 5- or 6-membered ring with a neighbouring carbon atom of Ar;


wherein optional substituents for Het and Ar are selected from halo, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, halo C_{1-4} alkyl, hydroxy C_{1-4} alkyl, hydroxy, aryl, amino, cyano, mercapto, C_{1-4} alkylamino, C_{1-4} dialkylamino, aryloxy, formyl, C_{1-4} alkylcarbonyl and C_{1-4} alkoxy carbonyl;

with the proviso that when Alk is a direct bond and A is O, S, CH_2O or a direct bond, then W is not O, S, OCH_2 or a direct bond.


2. (Original) A compound according to claim 1 wherein Het is a radical selected from:




(a-1)




(a-2)




(a-3)




(a-4)




(a-5)




(a-6)




(a-7)




(a-8)




(a-9)




(a-10)




(a-11)



(a-12)



(a-13)



(a-14)

wherein R¹ is hydrogen, C₁₋₆alkyl, halo, hydroxy, mercapto, haloC₁₋₄alkyl, amino, mono or di(C₁₋₆alkyl)amino, cyano, formyl, C₁₋₆alkoxy, hydroxyC₁₋₄ alkyl, C₁₋₄alkoxyC₁₋₄ alkyl, C₁₋₆ haloalkoxy, aryloxy, C₁₋₆alkylthio, arylthio, C₁₋₆alkylsulphinyl, C₁₋₆ alkylsulphonyl, arylsulphinyl, arylsulphonyl, -CH=NO-C₁₋₄alkyl, C₁₋₆alkoxycarbonyl, C₁₋₆alkylcarbonyl or aryl;


R² and R³ are each independently selected from hydrogen, C₁₋₆alkyl,

C₁₋₆alkoxy, halo or, in radicals (a-1), (a-4), (a-7) and (a-13), R¹ and R², or R² and R³ combined may represent a bivalent radical of formula -CH=CH-CH=CH- or (CH₂)_p where p is an integer from 2 to 4;

Y is O or S; and

Y' is O, S, SO or SO₂.


3. (Currently Amended) A compound according to ~~claim 1~~ claim 2 wherein Ar is a radical selected from




(c-1)




(c-2)



(c-3)



(c-4)



(c-5)




(c-6)

where Y is as defined above; and

R^{10} and R^{11} are each independently hydrogen, C_{1-6} alkyl, hydroxy C_{1-6} alkyl, halo, amino, cyano, nitro, C_{1-6} alkoxy, hydroxy, C_{1-6} alkylthio, or trifluoromethyl.

4. (Original) A compound according to claim 2 wherein Het is a radical of formula (a-1), (a-2) or (a-8).
5. (Original) A compound according to claim 2 wherein R^1 is selected from hydrogen, methyl, ethyl, chloro, methoxy and trifluoromethyl.
6. (Original) A compound according to claim 2 wherein R^2 and R^3 are independently hydrogen, chloro or methyl.
7. (Original) A compound according to claim 2 wherein Y is O or S.
8. (Original) A compound according to claim 1 wherein A is O, NH, NMe, a bond or a radical of formula (b-1).
9. (Original) A compound according to claim 1 wherein Z is CH or N.
10. (Currently Amended) A compound according to claim 1 wherein Alk is ~~C_{1-6} alkylene~~ divalent C_{1-6} alkyl or a direct bond.

11. (Original) A compound according to claim 1 wherein W is O.
12. (Original) A compound according to claim 3 wherein Ar is a radical of formula (c-1), (c-2) or (c-4).
13. (Original) A compound according to claim 3 wherein R^{10} and R^{11} are each independently H, methyl, chloro, hydroxy, methoxy, cyano or nitro.
14. (Original) A compound according to claim 3 wherein Y is O or S.
15. (Original) A compound according to claim 1 wherein X^1 is selected from C_{1-4} alkyl, C_{2-4} alkoxyalkyl, C_{3-4} alkenyl, C_{3-4} alkynyl, C_{1-4} haloalkyl, C_{3-4} haloalkenyl, C_{3-4} haloalkynyl or cyanomethyl.
16. (Original) A compound according to claim 1 wherein X^2 is selected from H, methyl or a bivalent radical of formula $(CH_2)_2$ or $(CH_2)_3$ which forms a 5- or 6-membered ring with the Ar group.
17. (Currently Amended) A compound of formula II:



wherein:

R^1 is hydrogen, C_{1-4} alkyl, halo, hydroxy, mercapto, trifluoromethyl, amino, mono or di(C_{1-4} alkyl)amino, cyano, formyl, $-CH=NO-C_{1-4}$ alkyl, C_{1-4} alkoxy, C_{1-4} haloalkoxy, aryloxy, C_{1-4} alkylthio, or aryl;

Z is CH or N;


Alk is C_{1-6} alkylene divalent C_{1-6} alkyl;

R^{10} and R^{11} are each independently hydrogen, C_{1-4} alkyl, C_{1-4} alkoxy, halo, hydroxy;

X^1 is C_{1-6} alkyl, C_{3-6} alkenyl, C_{3-6} haloalkenyl, C_{3-6} alkynyl, C_{3-6} haloalkynyl or C_{1-6} alkyl optionally substituted by halo, cyano, nitro, hydroxy, aryl, C_{1-4} alkoxy or C_{1-4} alkylthio; and

X^2 is hydrogen, cyano, C_{1-4} alkyl, C_{1-4} haloalkyl or X^2 is $-CH_2CH_2-$ or $-CH_2CH_2CH_2-$ forming a 5- or 6-membered ring with a carbon atom on the phenyl ring.

18. (Currently Amended) A compound of formula III:



wherein:

R^1 is hydrogen, C_{1-4} alkyl, halo, hydroxy, mercapto, trifluoromethyl, amino, mono or di(C_{1-4} alkyl)amino, cyano, formyl, $-CH=NO-C_{1-4}$ alkyl, C_{1-4} alkoxy, C_{1-4} haloalkoxy, aryloxy, C_{1-4} alkylthio, or aryl;

A is a bond or CH_2O ;


Alk is ~~C₁₋₇alkylene~~ divalent C₁₋₇alkyl;

R¹⁰ and R¹¹ are each independently hydrogen, C₁₋₄alkyl, C₁₋₄alkoxy, halo, hydroxy;

X¹ is C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₆haloalkenyl, C₃₋₆alkynyl, C₃₋₆haloalkynyl or C₁₋₆alkyl optionally substituted by halo, cyano, nitro, hydroxy, aryl, C₁₋₄alkoxy or C₁₋₄alkylthio; and

X² is hydrogen, cyano, C₁₋₄alkyl, C₁₋₄haloalkyl or X² is -CH₂CH₂- or -CH₂CH₂CH₂- forming a 5- or 6-membered ring with a carbon atom on the phenyl ring.

19. (Currently Amended) A compound of formula IV



wherein:

R¹ is hydrogen, C₁₋₄ alkyl, halo, hydroxy, mercapto, trifluoromethyl, amino, mono or di(C₁₋₄alkyl)amino, cyano, formyl, -CH=NO-C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkoxy, aryloxy, C₁₋₄alkylthio, or aryl;

Z is CH or N;


Alk is ~~C₁₋₆alkylene~~ divalent C₁₋₆alkyl;

R¹⁰ and R¹¹ are each independently hydrogen, C₁₋₄alkyl, C₁₋₄alkoxy, halo, hydroxy;

X¹ is C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₆haloalkenyl, C₃₋₆alkynyl, C₃₋₆haloalkynyl or C₁₋₆alkyl optionally substituted by halo, cyano, nitro, hydroxy, aryl, C₁₋₄alkoxy or C₁₋₄alkylthio; and

X² is hydrogen, cyano, C₁₋₄alkyl, C₁₋₄haloalkyl or X² is -CH₂CH₂- or -CH₂CH₂CH₂- forming a 5- or 6-membered ring with a carbon atom on the phenyl ring.

20. (Currently Amended) A compound of formula V



wherein:

Het is pyridyl, pyrazinyl, thiadiazolyl, benzoxazolyl, 1,3,5-triazinyl, pyrimidinyl or quinoxaliny, each of which may be optionally substituted with 1 to 3 substituents selected from halo, trifluoromethyl, C₁₋₄alkyl, C₁₋₄alkoxy or hydroxy;

Z is CH or N;


Alk is ~~C₁₋₆alkylene~~ divalent C₁₋₆alkyl;

R¹⁰ and R¹¹ are each independently hydrogen, C₁₋₄alkyl, C₁₋₄alkoxy, halo, hydroxy;

X¹ is C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₆haloalkenyl, C₃₋₆alkynyl, C₃₋₆haloalkynyl or C₁₋₆alkyl optionally substituted by halo, cyano, nitro, hydroxy, aryl, C₁₋₄alkoxy or C₁₋₄alkylthio; and

X² is hydrogen, cyano, C₁₋₄alkyl, C₁₋₄haloalkyl or X² is -CH₂CH₂- or -CH₂CH₂CH₂- forming a 5- or 6-membered ring with a carbon atom on the phenyl ring.

21. (Currently Amended) A compound of formula VI



wherein:

Het is pyridyl, pyrazinyl, thiadiazolyl, benzoxazolyl, 1,3,5-triazinyl, pyrimidinyl or quinoxaliny, each of which may be optionally substituted with 1 to 3 substituents selected from halo, trifluoromethyl, C₁₋₄alkyl, C₁₋₄alkoxy or hydroxy;

A is a direct bond, O, NH or NMe;

Alk is ~~C₁₋₆alkylene~~ divalent C₁₋₆alkyl;


R¹⁰ and R¹¹ are each independently hydrogen, C₁₋₄alkyl, C₁₋₄alkoxy, halo, hydroxy;

X¹ is C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₆haloalkenyl, C₃₋₆alkynyl, C₃₋₆haloalkynyl or C₁₋₆alkyl optionally substituted by halo, cyano, nitro, hydroxy, aryl, C₁₋₄alkoxy or C₁₋₄alkylthio; and

X² is hydrogen, cyano, C₁₋₄alkyl, C₁₋₄haloalkyl or X² is -CH₂CH₂- or -CH₂CH₂CH₂- forming a 5- or 6-membered ring with a carbon atom on the phenyl ring.

22. (Cancelled)

23. (Original) A compound of formula VII:



VII

where A, Alk, W, Ar and X^2 are as defined in claim 1, and X^3 is X^1 or an oxime protecting group.

24. (Original) A compound of formula X




where Het, A, Alk, W, Ar and X^2 are as defined in claim 1.

25. (Original) A composition comprising a compound of formula I according to claim 1 together with a pharmaceutically acceptable carrier.

26. (Original) A composition according to claim 25 which is a pharmaceutical composition.


27. (Currently Amended) A pharmaceutical composition comprising a compound of formula I




a salt thereof or a pharmaceutically acceptable derivative thereof where

Het is an optionally substituted 5- or 6-membered monocyclic heterocyclic radical or an optionally substituted 9- or 10-membered bicyclic heterocyclic radical, where each heterocyclic radical includes one or more heteroatoms selected from N, S and O;


A is O, S, NH, $N(C_{1-6}\text{alkyl})$, CH_2O , a direct bond or a bivalent heterocyclic radical of the formula




(b-1)



(b-2),



(b-3), or



(b-4)

where one or more of the carbon atoms within the radicals (b-1) to (b-4) may be optionally substituted with C_{1-6} alkyl or two carbon atoms in the radicals (b-1) to (b-4) may be bridged with a C_{2-4} alkylene divalent C_{2-4} alkyl radical, m and n are each independently integers of 1 to 4 inclusive with the proviso that the sum of m and n in radicals (b-1) to (b-4) is 3, 4 or 5;

Z is N or CR⁶ where R⁶ is hydrogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy or amino;

Z' is O, S, CHR⁷ or NR⁸ where R⁷ is hydrogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy or amino and R⁸ is hydrogen or C₁₋₆alkyl;

R⁴ is hydrogen or C₁₋₆alkyl; and

R⁵ is hydrogen, hydroxy, C₁₋₆alkyl or C₁₋₆alkoxy;

Alk is ~~C₁₋₇alkylene~~ divalent C₁₋₇alkyl or a direct bond;

W is O, S, OCH₂, a direct bond or NR⁹ where R⁹ is hydrogen or C₁₋₆alkyl;

Ar is an optionally substituted 5- or 6-membered monocyclic aryl radical or an optionally substituted 9- or 10-membered bicyclic aryl radical;


X¹ is C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₆haloalkenyl, C₃₋₆alkynyl, C₃₋₆haloalkynyl or C₁₋₆alkyl substituted by halo, cyano, nitro, hydroxy, aryl, C₁₋₄alkoxy, C₂₋₆alkoxyalkoxy, acyl or C₁₋₄alkylthio; and

X² is hydrogen, cyano, F, Cl, C₁₋₄alkyl, C₁₋₄haloalkyl or a bivalent radical of formula -(CH₂)₂-, -(CH₂)₃-, -CH₂O- or -(CH₂)₂O- which forms a 5- or 6-membered ring with a neighbouring carbon atom of Ar;

wherein optional substituents for Het and Ar are selected from halo, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, C₁₋₄alkoxy, haloC₁₋₄alkyl, hydroxyC₁₋₄alkyl, hydroxy, aryl, amino, cyano, mercapto, C₁₋₄alkylamino, C₁₋₄dialkylamino, aryloxy, formyl, C₁₋₄alkylcarbonyl and C₁₋₄alkoxycarbonyl;

a pharmaceutically acceptable carrier and further including a known anti-viral or anti-retroviral agent or other pharmaceutical used in the treatment of viral infections.



28. (Currently Amended) A method for the treatment or prophylaxis of a picornavirus infection in a mammal including the step of administering an effective amount of a compound of formula I




a salt thereof or a pharmaceutically acceptable derivative thereof where


Het is an optionally substituted 5- or 6-membered monocyclic heterocyclic radical or an optionally substituted 9- or 10-membered bicyclic heterocyclic radical, where each heterocyclic radical includes one or more heteroatoms selected from N, S and O;

A is O, S, NH, N(C₁₋₆alkyl), CH₂O, a direct bond or a bivalent heterocyclic radical of the formula





(b-3), or



(b-4)

where one or more of the carbon atoms within the radicals (b-1) to (b-4) may be optionally substituted with C_{1-6} alkyl or two carbon atoms in the radicals (b-1) to (b-4) may be bridged with a C_{2-4} alkylene divalent C_{2-4} alkyl radical, m and n are each independently integers of 1 to 4 inclusive with the proviso that the sum of m and n in radicals (b-1) to (b-4) is 3, 4 or 5;

Z is N or CR^6 where R^6 is hydrogen, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy or amino;

Z' is O, S, CHR^7 or NR^8 where R^7 is hydrogen, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy or amino and R^8 is hydrogen or C_{1-6} alkyl;

R^4 is hydrogen or C_{1-6} alkyl; and

R^5 is hydrogen, hydroxy, C_{1-6} alkyl or C_{1-6} alkoxy;

Alk is C_{4-7} alkylene divalent C_{1-7} alkyl or a direct bond;

W is O, S, OCH_2 , a direct bond or NR^9 where R^9 is hydrogen or C_{1-6} alkyl;

Ar is an optionally substituted 5- or 6-membered monocyclic aryl radical or an optionally substituted 9- or 10-membered bicyclic aryl radical;


X¹ is C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₆haloalkenyl, C₃₋₆alkynyl, C₃₋₆haloalkynyl or C₁₋₆alkyl substituted by halo, cyano, nitro, hydroxy, aryl, C₁₋₄alkoxy, C₂₋₆alkoxyalkoxy, acyl or C₁₋₄alkylthio; and

X² is hydrogen, cyano, F, Cl, C₁₋₄alkyl, C₁₋₄haloalkyl or a bivalent radical of formula -(CH₂)₂-, -(CH₂)₃-, -CH₂O- or -(CH₂)₂O- which forms a 5- or 6-membered ring with a neighbouring carbon atom of Ar;

wherein optional substituents for Het and Ar are selected from halo, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, C₁₋₄alkoxy, haloC₁₋₄alkyl, hydroxyC₁₋₄alkyl, hydroxy, aryl, amino, cyano, mercapto, C₁₋₄alkylamino, C₁₋₄dialkylamino, aryloxy, formyl, C₁₋₄alkylcarbonyl and C₁₋₄alkoxycarbonyl.

29. (Original) A method of claim 27 wherein the picornaviral infection is caused by one or more serotypes of rhinovirus.





30. (Currently Amended) Use of A method for preparing a pharmaceutical composition comprising admixing a compound of formula I



a salt thereof or a pharmaceutically acceptable derivative thereof where

Het is an optionally substituted 5- or 6-membered monocyclic heterocyclic radical or an optionally substituted 9- or 10-membered bicyclic heterocyclic radical, where each heterocyclic radical includes one or more heteroatoms selected from N, S and O;

A is O, S, NH, N(C₁₋₆alkyl), CH₂O, a direct bond or a bivalent heterocyclic radical of the formula



where one or more of the carbon atoms within the radicals (b-1) to (b-4) may be optionally substituted with C₁₋₆alkyl or two carbon atoms in the radicals (b-1) to (b-4) may be bridged with a ~~C₂₋₄alkylene~~ divalent C₂₋₄alkyl radical, m and n are each

independently integers of 1 to 4 inclusive with the proviso that the sum of m and n in radicals (b-1) to (b-4) is 3, 4 or 5;

Z is N or CR⁶ where R⁶ is hydrogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy or amino;

Z' is O, S, CHR⁷ or NR⁸ where R⁷ is hydrogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy or amino and R⁸ is hydrogen or C₁₋₆alkyl;

R⁴ is hydrogen or C₁₋₆alkyl; and

R⁵ is hydrogen, hydroxy, C₁₋₆alkyl or C₁₋₆alkoxy;

Alk is ~~C₁₋₇alkylene~~ divalent C₁₋₇alkyl or a direct bond;

W is O, S, OCH₂, a direct bond or NR⁹ where R⁹ is hydrogen or C₁₋₆alkyl;

Ar is an optionally substituted 5- or 6-membered monocyclic aryl radical or an optionally substituted 9- or 10-membered bicyclic aryl radical;

X¹ is C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₆haloalkenyl, C₃₋₆alkynyl, C₃₋₆haloalkynyl or C₁₋₆alkyl substituted by halo, cyano, nitro, hydroxy, aryl, C₁₋₄alkoxy, C₂₋₆alkoxyalkoxy, acyl or C₁₋₄alkylthio; and

X² is hydrogen, cyano, F, Cl, C₁₋₄alkyl, C₁₋₄haloalkyl or a bivalent radical of formula -(CH₂)₂-, -(CH₂)₃-, -CH₂O- or -(CH₂)₂O- which forms a 5- or 6-membered ring with a neighbouring carbon atom of Ar ~~in the manufacture of a medicament for the treatment or prophylaxis of picornavirus infection in mammals;~~

wherein optional substituents for Het and Ar are selected from halo, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, C₁₋₄alkoxy, haloC₁₋₄alkyl, hydroxyC₁₋₄alkyl, hydroxy, aryl, amino, cyano, mercapto, C₁₋₄alkylamino, C₁₋₄dialkylamino, aryloxy, formyl, C₁₋₄alkylcarbonyl and C₁₋₄alkoxycarbonyl;

with one or more pharmaceutically acceptable carriers therefore.

31. (Cancelled)

32. (New) A compound selected from the group consisting of the following:

4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

4-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

1-(4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-phenyl)-ethanone *O*-ethyl-oxime;

1-(4-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-phenyl)-ethanone *O*-ethyl-oxime;

4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-3-methoxy-benzaldehyde *O*-ethyl-oxime;

1-(4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-3,5-dimethoxy-phenyl)-ethanone *O*-ethyl-oxime;

4-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;

4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;

1-(4-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-phenyl)-ethanone *O*-methyl-oxime;

1-(4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-phenyl)-propan-1-one *O*-methyl-oxime;

4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-propyl-oxime;

4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-isopropyl-oxime;

4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-allyl-oxime;

[1-(4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-phenyl)-meth-(E)-ylideneaminoxy]-acetonitrile;

4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-benzyl-oxime;

4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-3,5-dimethyl-benzaldehyde *O*-methyl-oxime;

1-(4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-3-methoxy-phenyl)-ethanone *O*-methyl-oxime;

- 4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-[2-(2-ethoxy-ethyl)-oxime];
- 4-(2-{1-[6-(2,2,2-Trifluoro-ethoxy)-pyridazin-3-yl]-piperidin-4-yl}-ethoxy)-benzaldehyde *O*-ethyl-oxime;
- 4-{2-[1-(6-Methoxy-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;
- 4-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-ylmethoxy]-benzaldehyde *O*-benzyl-oxime;
- 4-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-ylmethoxy]-benzaldehyde *O*-allyl-oxime;
- 4-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-ylmethoxy]-benzaldehyde *O*-ethyl-oxime;
- 4-{3-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-propoxy}-benzaldehyde *O*-ethyl-oxime;
- 4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-3-methoxy-benzaldehyde *O*-methyl-oxime;
- 1-(4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-phenyl)-propan-1-one *O*-ethyl-oxime;
- 1-(4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-phenyl)-propan-1-one *O*-allyl-oxime;
- 4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-3-nitro-benzaldehyde *O*-ethyl-oxime;
- 4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-2-hydroxy-benzaldehyde *O*-ethyl-oxime;
- 4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-3-methyl-benzaldehyde *O*-ethyl-oxime;
- 4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-3-methyl-benzaldehyde *O*-allyl-oxime;
- 4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-3-methyl-benzaldehyde *O*-methyl-oxime;
- 4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-3,5-dimethyl-benzaldehyde *O*-ethyl-oxime;
- 4-[2-(1-Pyridazin-3-yl)-piperidin-4-yl]-ethoxy]-benzaldehyde *O*-ethyl-oxime;
- 4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-2-methoxy-benzaldehyde *O*-ethyl-oxime;
- 3-Methyl-4-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

3-Methyl-4-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;

3-Methyl-4-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-allyl-oxime;

3-Methyl-4-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-propyl-oxime;

4-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yloxy]-benzaldehyde *O*-ethyl-oxime;

4-{2-[1-(6-Phenyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

(*Z*)-4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

4-{2-[1-(6-Trifluoromethyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

4-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-(2,2,2-trifluoroethyl)-oxime;

4-{2-[1-(6-Methoxy-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-allyl-oxime;

4-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-propyl-oxime;

4-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-(2-methoxy-ethyl)-oxime;

4-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-allyl-oxime;

4-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-prop-2-ynyl-oxime;

4-{3-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-propoxy}-benzaldehyde *O*-methyl-oxime;

4-{3-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-propoxy}-benzaldehyde *O*-allyl-oxime;

4-{3-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-propoxy}-benzaldehyde *O*-methyl-oxime;

4-{3-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-propoxy}-benzaldehyde *O*-ethyl-oxime;

4-{3-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-propoxy}-benzaldehyde *O*-allyl-oxime;

4-{3-[1-(6-Trifluoromethyl-pyridazin-3-yl)-piperidin-4-yl]-propoxy}-benzaldehyde *O*-methyl-oxime;

4-[3-(1-Pyridazin-3-yl)-piperidin-4-yl]-propoxy]-benzaldehyde *O*-methyl-oxime;

4-[3-(1-Pyridazin-3-yl)-piperidin-4-yl]-propoxy]-benzaldehyde *O*-ethyl-oxime;

4-[3-(1-Pyridazin-3-yl)-piperidin-4-yl]-propoxy]-benzaldehyde *O*-allyl-oxime;

6-(4-{2-[4-(Ethoxyimino-methyl)-phenoxy]-ethyl}-piperidin-1-yl)-pyridazine-3-carbaldehyde;

4-{2-[1-(6-Hydroxymethyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;
4-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-(2-fluoro-ethyl)-oxime;
4-{2-[1-(6-Methyl-2-oxy-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;
4-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;
3-Hydroxy-4-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;
2,6-Dimethyl-4-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;
2,6-Dimethyl-4-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;
2-Methoxy-4-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;
2-Methyl-4-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;
2-Methyl-4-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;
2,5-Dimethyl-4-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;
2,5-Dimethyl-4-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;
2,3-Dimethyl-4-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;
2,3-Dimethyl-4-{2-[1-(6-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime; and
6-(4-{2-[4-(Ethoxyimino-methyl)-phenoxy]-ethyl}-piperidin-1-yl)-pyridazine-3-carbaldehyde *O*-methyl-oxime.

33. (New) A compound selected from the group consisting of the following:

3-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;

- 3-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-4-methoxy-benzaldehyde *O*-methyl-oxime;
- 3-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-5-hydroxy-benzaldehyde *O*-methyl-oxime;
- 3-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-5-hydroxy-benzaldehyde *O*-ethyl-oxime;
- 3-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-5-hydroxy-benzaldehyde *O*-allyl-oxime;
- 3-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;
- 3-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;
- 3-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-allyl-oxime;
- 3-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;
- 3-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-ylmethoxy]-benzaldehyde *O*-methyl-oxime;
- 3-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-ylmethoxy]-benzaldehyde *O*-ethyl-oxime;
- 3-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-ylmethoxy]-benzaldehyde *O*-allyl-oxime;
- 3-{3-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-propoxy}-benzaldehyde *O*-methyl-oxime;
- 3-{3-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-propoxy}-benzaldehyde *O*-ethyl-oxime;
- 3-{3-[1-(6-Chloro-pyridazin-3-yl)-piperidin-4-yl]-propoxy}-benzaldehyde *O*-allyl-oxime;
- 3-{3-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-propoxy}-benzaldehyde *O*-methyl-oxime;
- 3-{3-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-propoxy}-benzaldehyde *O*-ethyl-oxime;
- 3-{3-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-propoxy}-benzaldehyde *O*-allyl-oxime;
- 3-{3-[1-(6-Trifluoromethyl-pyridazin-3-yl)-piperidin-4-yl]-propoxy}-benzaldehyde *O*-methyl-oxime;
- 3-[3-(1-Pyridazin-3-yl)-piperidin-4-yl]-propoxy]-benzaldehyde *O*-methyl-oxime;
- 3-[3-(1-Pyridazin-3-yl)-piperidin-4-yl]-propoxy]-benzaldehyde *O*-ethyl-oxime;
- 3-[3-(1-Pyridazin-3-yl)-piperidin-4-yl]-propoxy]-benzaldehyde *O*-allyl-oxime; and
- 4-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-indan-1-one *O*-ethyl-oxime.

34. (New) A compound selected from the group consisting of the following:

wherein the compound is selected from the group consisting of the following:

3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-benzaldehyde *O*-methyl-oxime;

3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-benzaldehyde *O*-allyl-oxime;
3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-benzaldehyde *O*-ethyl-oxime;
3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-benzaldehyde *O*-benzyl-oxime;
4-[3-(3-Methyl-isoxazol-5-yl)-propoxy]-benzaldehyde *O*-ethyl-oxime;
1-{3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-phenyl}-ethanone *O*-methyl-oxime;
1-{3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-phenyl}-ethanone *O*-allyl-oxime;
1-{3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-phenyl}-ethanone *O*-allyl-oxime;
3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-benzaldehyde *O*-propyl-oxime;
1-{3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-phenyl}-propan-1-one *O*-methyl-oxime;
1-{3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-phenyl}-propan-1-one *O*-ethyl-oxime;
1-{3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-phenyl}-propan-1-one *O*-allyl-oxime;
1-{3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-phenyl}-ethanone *O*-ethyl-oxime;
3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-benzaldehyde *O*-isopropyl-oxime;
[1-{3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-phenyl}-meth-(E)-ylideneaminoxy]-acetonitrile;
3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-benzaldehyde *O*-prop-2-ynyl-oxime;
3,5-Dimethyl-4-[6-(3-methyl-isoxazol-5-yl)-hexyloxy]-benzaldehyde *O*-ethyl-oxime;
3,5-Dimethyl-4-[7-(3-methyl-isoxazol-5-yl)-heptyloxy]-benzaldehyde *O*-ethyl-oxime;
3,5-Dimethyl-4-[5-(3-methyl-isoxazol-5-yl)-pentyloxy]-benzaldehyde *O*-ethyl-oxime;
3,5-Dimethyl-4-[4-(3-methyl-isoxazol-5-yl)-butoxy]-benzaldehyde *O*-ethyl-oxime;
3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-benzaldehyde *O*-(2,2,2-trifluoro-ethyl)-oxime;
3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-benzaldehyde *O*-(2-ethoxy-ethyl)-oxime;
3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-benzaldehyde *O*-(2-oxo-propyl)-oxime;
3,5-Dimethyl-4-[3-(3-phenyl-isoxazol-5-yl)-propoxy]-benzaldehyde *O*-ethyl-oxime;
4-[3-(3-Ethyl-isoxazol-5-yl)-propoxy]-3,5-dimethyl-benzaldehyde *O*-ethyl-oxime;
3,5-Dimethyl-4-[3-(3-propyl-isoxazol-5-yl)-propoxy]-benzaldehyde *O*-ethyl-oxime;
4-[2-(3-Ethyl-isoxazol-5-yl)-ethoxy]-3,5-dimethyl-benzaldehyde *O*-ethyl-oxime;
3-Methyl-4-[2-(3-propyl-isoxazol-5-yl)-ethoxy]-benzaldehyde *O*-ethyl-oxime;
3,5-Dimethyl-4-[3-(3-methyl-isoxazol-5-yl)-propoxy]-benzaldehyde *O*-(2-fluoro-ethyl)-oxime;

4-[3-(3-Cyclopropyl-isoxazol-5-yl)-propoxy]-3,5-dimethyl-benzaldehyde *O*-ethyl-oxime;
4-[4-(3-Ethyl-isoxazol-5-yl)-butoxy]-3,5-dimethyl-benzaldehyde *O*-ethyl-oxime; and
3,5-Dimethyl-4-[4-(3-propyl-isoxazol-5-yl)-butoxy]-benzaldehyde *O*-ethyl-oxime.

35. (New) A compound selected from the group consisting of the following:

4-{2-[4-(6-Chloro-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;
4-[2-(4-Pyridazin-3-yl-piperazin-1-yl)-ethoxy]-benzaldehyde *O*-ethyl-oxime;
3-[2-(4-Pyridazin-3-yl-piperazin-1-yl)-ethoxy]-benzaldehyde *O*-ethyl-oxime;
4-[2-(4-Pyridazin-3-yl-piperazin-1-yl)-ethoxy]-benzaldehyde *O*-allyl-oxime;
4-{2-[4-(6-Methyl-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;
4-{2-[4-(6-Methyl-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;
4-{2-[4-(6-Methyl-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-allyl-oxime;
3-{2-[4-(6-Methyl-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;
3-{2-[4-(6-Methyl-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;
3-{2-[4-(6-Methyl-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-allyl-oxime;
4-{2-[4-(6-Chloro-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;
4-{2-[4-(6-Chloro-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-allyl-oxime;
3-{2-[4-(6-Chloro-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;
3-{2-[4-(6-Chloro-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;
3-{2-[4-(6-Chloro-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-allyl-oxime;
4-{2-[4-(6-Trifluoromethyl-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;
4-{2-[4-(6-Trifluoromethyl-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;
4-{2-[4-(6-Trifluoromethyl-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-allyl-oxime;
3-{2-[4-(6-Trifluoromethyl-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;
3-{2-[4-(6-Trifluoromethyl-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

3-{2-[4-(6-Trifluoromethyl-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-allyl-oxime;

4-{2-[4-(6-Methyl-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-propyl-oxime;

3-{2-[4-(6-Methyl-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-propyl-oxime;

4-{2-[4-(6-Chloro-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-propyl-oxime; and

3-{2-[4-(6-Chloro-pyridazin-3-yl)-piperazin-1-yl]-ethoxy}-benzaldehyde *O*-propyl-oxime.

36. (New) A compound selected from the group consisting of the following:

4-[1-(6-Chloro-pyridazin-3-yl)-piperidin-3-ylmethoxy]-benzaldehyde *O*-ethyl-oxime;

4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-3-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;

4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-3-yl]-ethoxy}-benzaldehyde *O*-allyl-oxime;

4-{2-[1-(6-Chloro-pyridazin-3-yl)-piperidin-3-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;

4-{3-[1-(6-Chloro-pyridazin-3-yl)-piperidin-3-yl]-propoxy}-benzaldehyde *O*-ethyl-oxime;

4-{3-[1-(6-Chloro-pyridazin-3-yl)-piperidin-3-yl]-propoxy}-benzaldehyde *O*-allyl-oxime;

4-{3-[1-(6-Trifluoromethyl-pyridazin-3-yl)-piperidin-3-yl]-propoxy}-benzaldehyde *O*-methyl-oxime;

4-{3-[1-(6-Trifluoromethyl-pyridazin-3-yl)-piperidin-3-yl]-propoxy}-benzaldehyde *O*-ethyl-oxime;

4-{3-[1-(6-Trifluoromethyl-pyridazin-3-yl)-piperidin-3-yl]-propoxy}-benzaldehyde *O*-allyl-oxime;

3-{3-[1-(6-Trifluoromethyl-pyridazin-3-yl)-piperidin-3-yl]-propoxy}-benzaldehyde *O*-methyl-oxime;

3-{3-[1-(6-Trifluoromethyl-pyridazin-3-yl)-piperidin-3-yl]-propoxy}-benzaldehyde *O*-ethyl-oxime;

3-{3-[1-(6-Trifluoromethyl-pyridazin-3-yl)-piperidin-3-yl]-propoxy}-benzaldehyde *O*-allyl-oxime;

4-{3-[1-(6-Methyl-pyridazin-3-yl)-piperidin-3-yl]-propoxy}-benzaldehyde *O*-allyl-oxime;

3-{3-[1-(6-Methyl-pyridazin-3-yl)-piperidin-3-yl]-propoxy}-benzaldehyde *O*-methyl-oxime;

3-{3-[1-(6-Methyl-pyridazin-3-yl)-piperidin-3-yl]-propoxy}-benzaldehyde *O*-ethyl-oxime;

3-{3-[1-(6-Methyl-pyridazin-3-yl)-piperidin-3-yl]-propoxy}-benzaldehyde *O*-allyl-oxime;

4-[1-(6-Chloro-pyridazin-3-yl)-piperidin-3-ylmethoxy]-benzaldehyde *O*-methyl-oxime;

4-[1-(6-Chloro-pyridazin-3-yl)-piperidin-3-ylmethoxy]-benzaldehyde *O*-allyl-oxime;
3-[1-(6-Chloro-pyridazin-3-yl)-piperidin-3-ylmethoxy]-benzaldehyde *O*-methyl-oxime;
3-[1-(6-Chloro-pyridazin-3-yl)-piperidin-3-ylmethoxy]-benzaldehyde *O*-ethyl-oxime;
3-[1-(6-Chloro-pyridazin-3-yl)-piperidin-3-ylmethoxy]-benzaldehyde *O*-allyl-oxime;
4-[1-(6-Trifluoromethyl-pyridazin-3-yl)-piperidin-3-ylmethoxy]-benzaldehyde *O*-methyl-oxime;
4-[1-(6-Trifluoromethyl-pyridazin-3-yl)-piperidin-3-ylmethoxy]-benzaldehyde *O*-ethyl-oxime;
4-[1-(6-Trifluoromethyl-pyridazin-3-yl)-piperidin-3-ylmethoxy]-benzaldehyde *O*-allyl-oxime;
3-[1-(6-Trifluoromethyl-pyridazin-3-yl)-piperidin-3-ylmethoxy]-benzaldehyde *O*-methyl-oxime;
3-[1-(6-Trifluoromethyl-pyridazin-3-yl)-piperidin-3-ylmethoxy]-benzaldehyde *O*-ethyl-oxime;
and
3-[1-(6-Trifluoromethyl-pyridazin-3-yl)-piperidin-3-ylmethoxy]-benzaldehyde *O*-allyl-oxime.

37. (New) A compound selected from the group consisting of the following:

4-[2-(5'-Trifluoromethyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-ethoxy]-benzaldehyde
O-ethyl-oxime;
4-[2-(5'-Chloro-2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-yl)-ethoxy]-benzaldehyde *O*-ethyl-oxime;
4-{2-[1-(5-Trifluoromethyl-[1,3,4]thiadiazol-2-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-
methyl-oxime;
4-{2-[1-(5-Trifluoromethyl-[1,3,4]thiadiazol-2-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-
ethyl-oxime;
4-{2-[1-(5-Methyl-[1,3,4]thiadiazol-2-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-methyl-
oxime;
4-{2-[1-(5-Methyl-[1,3,4]thiadiazol-2-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;
4-{2-[1-(5-Chloro-pyrazin-2-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;
4-{2-[1-(5-Chloro-pyrazin-2-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;
4-[2-(6'-Methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-yl)-ethoxy]-benzaldehyde *O*-ethyl-
oxime;
2-(4-{2-[4-(Methoxyimino-methyl)-phenoxy]-ethyl}-piperidin-1-yl)-thiazole-4-carboxylic acid
ethyl ester;
2-(4-{2-[4-(Ethoxyimino-methyl)-phenoxy]-ethyl}-piperidin-1-yl)-thiazole-4-carboxylic acid
ethyl ester;

4-{2-[1-(6-Chloro-pyrazin-2-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;
4-[2-(1-Benzooxazol-2-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;
4-[2-(1-Benzooxazol-2-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;
4-{2-[1-(4,6-Dimethoxy-[1,3,5]triazin-2-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;
4-{2-[1-(4,6-Dimethoxy-[1,3,5]triazin-2-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;
4-{2-[1-(5-Ethyl-pyrimidin-2-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;
4-{2-[1-(5-Ethyl-pyrimidin-2-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;
4-[2-(1-Benzothiazol-2-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-methyl-oxime;
4-[2-(1-Benzothiazol-2-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime;
4-{2-[1-(6-Chloro-quinoxalin-2-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime; and
4-{2-[1-(6-Chloro-5-methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-benzaldehyde *O*-ethyl-oxime.

38. (New) A compound selected from the following:

4-[5-(6-Chloro-pyridazin-3-ylamino)-pentyloxy]-benzaldehyde *O*-ethyl-oxime;
4-{5-[(6-Chloro-pyridazin-3-yl)-methyl-amino]-pentyloxy}-benzaldehyde *O*-ethyl-oxime;
4-[6-(6-Chloro-pyridazin-3-ylamino)-hexyloxy]-benzaldehyde *O*-ethyl-oxime;
4-[4-(6-Chloro-pyridazin-3-ylamino)-butoxy]-benzaldehyde *O*-ethyl-oxime;
4-{6-[(6-Chloro-pyridazin-3-yl)-methyl-amino]-hexyloxy}-benzaldehyde *O*-methyl-oxime;
4-{4-[(6-Chloro-pyridazin-3-yl)-methyl-amino]-butoxy}-benzaldehyde *O*-ethyl-oxime;
4-[5-(6-Chloro-pyridazin-3-yloxy)-pentyloxy]-benzaldehyde *O*-ethyl-oxime; and
4-(6-Chloro-quinoxalin-2-yloxy)-benzaldehyde *O*-ethyl-oxime.

39. (New) A compound selected from the following:

2-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-thiazole-4-carbaldehyde *O*-ethyl-oxime; and
2-{2-[1-(6-Methyl-pyridazin-3-yl)-piperidin-4-yl]-ethoxy}-thiazole-4-carbaldehyde *O*-methyl-oxime.